MovDisordV3, Main, Exploration, bibRecord, 002779

Long‐term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay

Identifieur interne : 002779 ( Main/Exploration ); précédent : 002778; suivant : 002780

Long‐term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay

Auteurs : Mitchell F. Brin [États-Unis] ; Cynthia L. Comella [États-Unis] ; Joseph Jankovic [États-Unis] ; Francis Lai [États-Unis] ; Markus Naumann [Allemagne]

Source :

Movement Disorders [ 0885-3185 ] ; 2008-07-30.

RBID : ISTEX:7F5394ADC5C0380BAF590A913BA9FE12405F25D3

Descripteurs français

Pascal (Inist)
- Animal, Bontoxilysin, Dystonie, Immunogénicité, Long terme, Pathologie du système nerveux, Souris, Traitement.

English descriptors

KwdEn :
- Adult, Aged, Aged, 80 and over, Animal, Animals, Antibodies, Bacterial (biosynthesis), Antibodies, Bacterial (immunology), Antibody Specificity, Biological Assay, Bontoxilysin, Botulinum Toxins, Type A (administration & dosage), Botulinum Toxins, Type A (adverse effects), Botulinum Toxins, Type A (immunology), Botulinum Toxins, Type A (therapeutic use), Dystonia, Female, Follow-Up Studies, Humans, Immunogenicity, Injections, Intramuscular, Long term, Male, Mice, Middle Aged, Mouse, Nervous system diseases, Neutralization Tests, Prospective Studies, Torticollis (drug therapy), Torticollis (immunology), Treatment, antigenicity, botulinum toxin, cervical dystonia, immunogenicity, neutralizing antibodies.
MESH :
- chemical , administration & dosage : Botulinum Toxins, Type A.
- chemical , adverse effects : Botulinum Toxins, Type A.
- chemical , biosynthesis : Antibodies, Bacterial.
- chemical , immunology : Antibodies, Bacterial, Botulinum Toxins, Type A.
- chemical , therapeutic use : Botulinum Toxins, Type A.
- drug therapy : Torticollis.
- immunology : Torticollis.
- Adult, Aged, Aged, 80 and over, Animals, Antibody Specificity, Biological Assay, Female, Follow-Up Studies, Humans, Injections, Intramuscular, Male, Mice, Middle Aged, Neutralization Tests, Prospective Studies.

Abstract

To evaluate the immunogenicity of botulinum toxin type A (BoNTA; BOTOX) in cervical dystonia (CD). Subjects diagnosed with CD for ≥1 year and previously naïve to BoNTs were treated with BoNTA in a prospective, open‐label, multicenter study. Serum samples were analyzed for BoNTA neutralizing antibodies using the Mouse Protection Assay (MPA). Clinical resistance was assessed with a test injection of 20 U BoNTA placed unilaterally into the frontalis (Frontalis Antibody Test; FTAT) or corrugator muscle (Unilateral Brow Injection; UBI). Efficacy was assessed and adverse events were recorded. Of 326 subjects enrolled, 251 (77%) completed the study. Subjects received a median of 9 BoNTA treatments (mean dose per session ranged from 148.4 to 213.0 U over a mean of 2.5 years [range: 3.2 months–4.2 years]). Only 4 of 326 subjects (1.2%) tested positive for antibodies in the MPA; three of these subjects stopped responding clinically to BoNTA (of whom one also showed clinical resistance in the FTAT) and one continued to respond. Consistent improvements in the signs/symptoms of CD were noted. The most frequent treatment‐related adverse events were mild to moderate weakness, dysphagia, neck pain, and injection‐site pain. The current formulation of BoNTA rarely causes neutralizing antibody formation in CD subjects treated ≤4 years. © 2008 Movement Disorder Society

Url:

https://api.istex.fr/document/7F5394ADC5C0380BAF590A913BA9FE12405F25D3/fulltext/pdf

DOI: 10.1002/mds.22157

Affiliations:

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Long‐term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay</title>
<author><name sortKey="Brin, Mitchell F" sort="Brin, Mitchell F" uniqKey="Brin M" first="Mitchell F." last="Brin">Mitchell F. Brin</name>
</author>
<author><name sortKey="Comella, Cynthia L" sort="Comella, Cynthia L" uniqKey="Comella C" first="Cynthia L." last="Comella">Cynthia L. Comella</name>
</author>
<author><name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name>
<affiliation><country>États-Unis</country>
<placeName><settlement type="city">Houston</settlement>
<region type="state">Texas</region>
</placeName>
<orgName type="university" n="3">Baylor College of Medicine</orgName>
</affiliation>
</author>
<author><name sortKey="Lai, Francis" sort="Lai, Francis" uniqKey="Lai F" first="Francis" last="Lai">Francis Lai</name>
</author>
<author><name sortKey="Naumann, Markus" sort="Naumann, Markus" uniqKey="Naumann M" first="Markus" last="Naumann">Markus Naumann</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:7F5394ADC5C0380BAF590A913BA9FE12405F25D3</idno>
<date when="2008" year="2008">2008</date>
<idno type="doi">10.1002/mds.22157</idno>
<idno type="url">https://api.istex.fr/document/7F5394ADC5C0380BAF590A913BA9FE12405F25D3/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000827</idno>
<idno type="wicri:Area/Istex/Curation">000827</idno>
<idno type="wicri:Area/Istex/Checkpoint">001335</idno>
<idno type="wicri:doubleKey">0885-3185:2008:Brin M:long:term:treatment</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:18546321</idno>
<idno type="wicri:Area/PubMed/Corpus">002194</idno>
<idno type="wicri:Area/PubMed/Curation">002194</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002231</idno>
<idno type="wicri:Area/Ncbi/Merge">002169</idno>
<idno type="wicri:Area/Ncbi/Curation">002169</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">002169</idno>
<idno type="wicri:Area/Main/Merge">003357</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:08-0417083</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001162</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001B57</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">001204</idno>
<idno type="wicri:doubleKey">0885-3185:2008:Brin M:long:term:treatment</idno>
<idno type="wicri:Area/Main/Merge">003812</idno>
<idno type="wicri:Area/Main/Curation">002779</idno>
<idno type="wicri:Area/Main/Exploration">002779</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Long‐term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay</title>
<author><name sortKey="Brin, Mitchell F" sort="Brin, Mitchell F" uniqKey="Brin M" first="Mitchell F." last="Brin">Mitchell F. Brin</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Allergan, Inc., Global Drug Development, Irvine, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>University of California, Irvine, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Comella, Cynthia L" sort="Comella, Cynthia L" uniqKey="Comella C" first="Cynthia L." last="Comella">Cynthia L. Comella</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Rush University Medical Center, Chicago, Illinois</wicri:regionArea>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Parkinson's Disease Center and Movement Disorders Clinic at Baylor College of Medicine, Houston, Texas</wicri:regionArea>
<placeName><region type="state">Texas</region>
</placeName>
<placeName><settlement type="city">Houston</settlement>
<region type="state">Texas</region>
</placeName>
<orgName type="university" n="3">Baylor College of Medicine</orgName>
</affiliation>
</author>
<author><name sortKey="Lai, Francis" sort="Lai, Francis" uniqKey="Lai F" first="Francis" last="Lai">Francis Lai</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Biostatistics, Allergan, Inc., Irvine, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Naumann, Markus" sort="Naumann, Markus" uniqKey="Naumann M" first="Markus" last="Naumann">Markus Naumann</name>
<affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Klinikum Augsburg, Augsburg</wicri:regionArea>
<placeName><region type="land" nuts="1">Bavière</region>
<region type="district" nuts="2">District de Souabe</region>
<settlement type="city">Augsbourg</settlement>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2008-07-30">2008-07-30</date>
<biblScope unit="vol">23</biblScope>
<biblScope unit="issue">10</biblScope>
<biblScope unit="page" from="1353">1353</biblScope>
<biblScope unit="page" to="1360">1360</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">7F5394ADC5C0380BAF590A913BA9FE12405F25D3</idno>
<idno type="DOI">10.1002/mds.22157</idno>
<idno type="ArticleID">MDS22157</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Animal</term>
<term>Animals</term>
<term>Antibodies, Bacterial (biosynthesis)</term>
<term>Antibodies, Bacterial (immunology)</term>
<term>Antibody Specificity</term>
<term>Biological Assay</term>
<term>Bontoxilysin</term>
<term>Botulinum Toxins, Type A (administration & dosage)</term>
<term>Botulinum Toxins, Type A (adverse effects)</term>
<term>Botulinum Toxins, Type A (immunology)</term>
<term>Botulinum Toxins, Type A (therapeutic use)</term>
<term>Dystonia</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Immunogenicity</term>
<term>Injections, Intramuscular</term>
<term>Long term</term>
<term>Male</term>
<term>Mice</term>
<term>Middle Aged</term>
<term>Mouse</term>
<term>Nervous system diseases</term>
<term>Neutralization Tests</term>
<term>Prospective Studies</term>
<term>Torticollis (drug therapy)</term>
<term>Torticollis (immunology)</term>
<term>Treatment</term>
<term>antigenicity</term>
<term>botulinum toxin</term>
<term>cervical dystonia</term>
<term>immunogenicity</term>
<term>neutralizing antibodies</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Botulinum Toxins, Type A</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Botulinum Toxins, Type A</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="biosynthesis" xml:lang="en"><term>Antibodies, Bacterial</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies, Bacterial</term>
<term>Botulinum Toxins, Type A</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Botulinum Toxins, Type A</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Torticollis</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Torticollis</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Animals</term>
<term>Antibody Specificity</term>
<term>Biological Assay</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Injections, Intramuscular</term>
<term>Male</term>
<term>Mice</term>
<term>Middle Aged</term>
<term>Neutralization Tests</term>
<term>Prospective Studies</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Animal</term>
<term>Bontoxilysin</term>
<term>Dystonie</term>
<term>Immunogénicité</term>
<term>Long terme</term>
<term>Pathologie du   système nerveux</term>
<term>Souris</term>
<term>Traitement</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">To evaluate the immunogenicity of botulinum toxin type A (BoNTA; BOTOX) in cervical dystonia (CD). Subjects diagnosed with CD for ≥1 year and previously naïve to BoNTs were treated with BoNTA in a prospective, open‐label, multicenter study. Serum samples were analyzed for BoNTA neutralizing antibodies using the Mouse Protection Assay (MPA). Clinical resistance was assessed with a test injection of 20 U BoNTA placed unilaterally into the frontalis (Frontalis Antibody Test; FTAT) or corrugator muscle (Unilateral Brow Injection; UBI). Efficacy was assessed and adverse events were recorded. Of 326 subjects enrolled, 251 (77%) completed the study. Subjects received a median of 9 BoNTA treatments (mean dose per session ranged from 148.4 to 213.0 U over a mean of 2.5 years [range: 3.2 months–4.2 years]). Only 4 of 326 subjects (1.2%) tested positive for antibodies in the MPA; three of these subjects stopped responding clinically to BoNTA (of whom one also showed clinical resistance in the FTAT) and one continued to respond. Consistent improvements in the signs/symptoms of CD were noted. The most frequent treatment‐related adverse events were mild to moderate weakness, dysphagia, neck pain, and injection‐site pain. The current formulation of BoNTA rarely causes neutralizing antibody formation in CD subjects treated ≤4 years. © 2008 Movement Disorder Society</div>
</front>
</TEI>
<affiliations><list><country><li>Allemagne</li>
<li>États-Unis</li>
</country>
<region><li>Bavière</li>
<li>Californie</li>
<li>District de Souabe</li>
<li>Illinois</li>
<li>Texas</li>
</region>
<settlement><li>Augsbourg</li>
<li>Houston</li>
</settlement>
<orgName><li>Baylor College of Medicine</li>
</orgName>
</list>
<tree><country name="États-Unis"><region name="Californie"><name sortKey="Brin, Mitchell F" sort="Brin, Mitchell F" uniqKey="Brin M" first="Mitchell F." last="Brin">Mitchell F. Brin</name>
</region>
<name sortKey="Brin, Mitchell F" sort="Brin, Mitchell F" uniqKey="Brin M" first="Mitchell F." last="Brin">Mitchell F. Brin</name>
<name sortKey="Comella, Cynthia L" sort="Comella, Cynthia L" uniqKey="Comella C" first="Cynthia L." last="Comella">Cynthia L. Comella</name>
<name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name>
<name sortKey="Lai, Francis" sort="Lai, Francis" uniqKey="Lai F" first="Francis" last="Lai">Francis Lai</name>
</country>
<country name="Allemagne"><region name="Bavière"><name sortKey="Naumann, Markus" sort="Naumann, Markus" uniqKey="Naumann M" first="Markus" last="Naumann">Markus Naumann</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002779 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002779 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:7F5394ADC5C0380BAF590A913BA9FE12405F25D3
   |texte=   Long‐term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

Movement Disorders (revue)

Long‐term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay

Long‐term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.